Skip to main content
TipRanks
Go Ultimate75% OFF
ReCode Therapeutics logo

ReCode Therapeutics: Valuation, Funding & Investors

BuySell

ReCode Therapeutics is a clinical-stage genetic medicines company specializing in the precision delivery of mRNA and gene correction therapeutics. Utilizing its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform, ReCode aims to enhance the efficacy and potency of genetic medicines by targeting specific organs, tissues, and cells implicated in diseases. The company's lead programs focus on developing inhaled mRNA-based therapies for cystic fibrosis and primary ciliary dyskinesia, addressing genetic mutations that are unresponsive to existing treatments.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$29M
Total Funding Rounds
1
Latest Funding Amount
$29M
Latest Funding Round
Investment

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Sep 29, 2025Investment$29.00M―

Investors

Investor NameFunding Round
Cystic Fibrosis FoundationInvestment

Similar Companies

A snapshot of private companies similar to ReCode Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis